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vs. MPT via MP showed a statistically not significant advantage for VMP regarding 
survival outcomes. Significant benefits were observed for CR and development of 
any grade 3-4 AEs favouring VMP. ConClusions: Analysis of both aggregated and 
individual patient data essentially lead to the same conclusions, i.e. VMP and MPT 
seem more effective than MP, VMP seems ahead of MPT regarding response criteria 
and adverse events. We found significant between-trials heterogeneity, however 
no consistent relationship of effect and study-level covariates (e.g. maintenance 
dosing) was apparent. Thus, we relied on the random effects approach to meta-
analysis to cope with the unexplained trial-to-trial variability. Our results may best 
be confirmed by a head-to-head trial of VMP vs. MPT.
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What is the CliNiCal effeCtiveNess aNd Cost- effeCtiveNess 
of erythroPoietiN-stimulatiNg ageNts for the treatmeNt of 
PatieNts With CaNCer-treatmeNt iNduCed aNaemia? iNsights from 
Cumulative meta-aNalyses (Cma) aNd lessoNs for Cost-effeCtiveNess 
aNalyses
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objeCtives: A health technology assessment (HTA) informing the recent NICE 
guidance regarding the use of erythropoiesis-stimulating agents (ESA) in cancer-
treatment induced anaemia (CIA) identified uncertainty around the overall survival 
hazard ratio (OSHR). We investigated how the understanding of OS in CIA patients 
treated with ESAs has shaped over time and the effects of accumulating OS evidence 
on cost-effectiveness. In addition, the effects of narrowing inclusion criteria, by com-
paring the HTA results to a recent Cochrane review, were investigated. Methods: 
CMA was applied to both HTA review and Cochrane review OS data to identify pat-
terns in results; study results were accumulated by the year of publication. Annual 
OSHR results from the CMA were applied to an economic model developed in the 
HTA to calculate the cost-effectiveness of ESAs. Results: Precision of the OSHR 
estimate appeared to improve with additional evidence, but the true location of the 
estimate remained uncertain and the best estimate varied over time. Using the HTA 
CMA, results from 2001 and 2002 suggested survival benefits to using ESAs (0.77, 95% 
CI 0.60–0.98 and 0.78, 95% CI 0.65–0.93 respectively), with ESAs being cost-effective 
at a willingness to pay threshold of £30,000 per QALY for all values of the OSHR 95% 
CI. HTA CMA for all other years and all Cochrane CMA results did not suggest any 
significant effects of ESAs on OS. Cost-effectiveness results were therefore uncer-
tain. ConClusions: Current evidence suggests we cannot reject the possibility 
of no difference in OS between patients receiving or not receiving ESAs, regardless 
of study inclusion criteria. However, there is also insufficient evidence to support 
such conclusions, particularly as earlier results from narrower inclusion criteria sug-
gested some survival benefits. This analysis highlights the additional uncertainty of 
the current evidence base on cost-effectiveness analyses, which cannot be captured 
in standard sensitivity analyses.
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objeCtives: The question of sequencing multiple myeloma (MM) treatments is a 
key one, as is the retreatment in patients where the same treatment was effective 
in earlier lines. We investigated bortezomib retreatment in a Swedish MM national 
registry. Methods: Patients diagnosed with MM since January 2000 until June 2011 
from 7 university clinics, 5 regional centers and 3 local hospitals in Sweden were 
included. Time to response and overall survival (OS) were analyzed using stratified 
Kaplan-Meier analysis. Results: Of the 541 patients treated with bortezomib (out 
of a total population of n= 1638), 93 were retreated with bortezomib. Median follow-
up from start of retreatment was 10.2 mos. Median age was 63.5 (range 38–83), 57.3% 
were male, 34.2%/15.9%/20.7% had stage I/II/III disease (ISS); median number of 
prior therapies at initial bortezomib and retreatment was 1 and 3. 26.8%/32.9% of 
pts initiated retreatment as 3rd/4th line therapy. 37.8%/22.0% initiated bortezomib 
retreatment in combination with dexamethasone, 7.3% in monotherapy, compared 
to 40.3%, 21.8% and 8.5%, at initial bortezomib. ≥ PR/VGPR-rates at re-treatment were 
59.1%/12.7%, compared to 82.0%/39.9% at initial bortezomib. Median time to ≥ PR/
VGPR was 2.4/1.3 months at retreatment versus 1.9/2.1 at initial bortezomib. The 
≥ PR rate at retreatment was numerically longer in patients with < = 2 (75.1%) vs > = 3 
(20%) therapies prior to retreatment. Median PFS/OS from start of re-treatment was 
5.5 [95%CI: 3.7, 10.0]/17.4 [10.3, 26] months, compared to 8.1 [6.9, 9.7]/25.9 months 
[21.0, 31.6] for initial bortezomib. Number of prior therapies at retreatment did not 
affect PFS; however, OS was longer in pts with fewer prior therapies (p= 0.0112). 
There was a trend towards longer PFS (p= 0.087) in retreated patients who achieved 
> = PR compared to non-responders. ConClusions: These data suggest that, in 
everyday medical practice, bortezomib retreatment is effective in relapsed/refrac-
tory MM, with more than half of pts who responded to initial bortezomib achieving 
≥ PR at retreatment.
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objeCtives: The aim was at assembling published evidence on treatments for RAS 
wild-type (wt) (KRAS and NRAS exon 2,3,4) metastatic colorectal cancer (mCRC) 
to evaluate the efficacy and safety of cetuximab in combination with FOLFOX or 
FOLFIRI chemotherapy as first line treatment of these patients. The outcomes of 
interest were progression free survival (PFS), overall survival (OS), overall response 
(ORR), and adverse event data. Methods: A systematic literature search was per-
formed on the 24th March 2014 in Medline, Embase, and The Cochrane Library to 
identify all randomized controlled trials (RCTs) as well as single arm trials concern-
ing the efficacy and safety of first line interventions of interest in patients with 
RAS wt mCRC. Abstract and article selection was performed by two independent 
researchers, with a third person resolving disagreements, according to predefined 
standards, which were based on criteria for patient, intervention, comparator, 
outcomes and study design (PICOS). Results: 596 citations were identified after 
removing duplicates. 520 citations were excluded for reasons including: patient 
population (231), study design (174), intervention (74), outcomes (23) and duplicates 
(18). A total of 76 abstracts were included and the full-text version of these publica-
tions were retrieved and screened resulting in excluding 69 further publications due 
to the study design (20), patient population (43), outcomes (5), and one (1) duplicate, 
not being in line with the review selection criteria. Ten citations on five different 
RCTs were identified that met the inclusion criteria. ConClusions: This system-
atic review provided the latest studies on RAS wild-type (wt) metastatic colorectal 
cancer (mCRC) treatments. Despite the small number of studies available for a 
relatively new biomarker-specific mCRC, anti- EGFR treatments such as cetuximab 
in combination with FOLFOX and FOLFIRI have demonstrated a significant benefit 
in progression free survival (PFS), overall survival (OS) and overall response rate 
(ORR) versus chemotherapy alone in mCRC RAS wt patients.
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objeCtives: Malignant pleural mesothelioma (MPM) is a rare tumour with a poor 
survival and prognosis. In Russia, the epidemiology of this disease has not been well 
studied. We conducted an epidemiological study to understand the characteristics of 
patients with MPM in Russia. Methods: Retrospective study of the characteristics 
of patients with MPM. Patients treated for 1st and 2ndline therapy were included 
in ten centers of the Russian Federation. The data were generated from hospital 
records, electronic databases, and other sources of information between June and 
December in 2013. Results: One hundred and twelve patients were enrolled. The 
average age was 60.0±10.87 years and 42% were women. Harmful work environ-
ment was indicated in 21/112 (18.8%) of the patients. The exposure to asbestos was 
reported in 10/112 (8.9%) patients, and contact with erionite in 8/112 (7.1%) patients. 
Fifty percent (56/112) of the patients were smokers or are current smokers; smoking 
period was 25.3±13.25 years. The disease stage at diagnosis was I-II in 31 (27.6%), 
III-IV in 81 (72.4 %) patients. The ECOG performance status was 0 in 16 (14.3%), 
1 in 46 (41.1%), 2 in 30 (26.8%), 3 in 15 (13.4%) and 4 in 1 (0.9%) patients, in 4 patients 
- unknown. 50/112 (44.6%) patients had immunohistochemical verification of the 
diagnosis. Antineoplastic drugs were used to treat 85/112 (75.9%) patients. The main 
drugs used were cisplatin (n= 75), gemcitabine (32), doxorubicin (34), pemetrexed 
(29) and carboplatin (21). ConClusions: In Russia, the majority of MPM patients 
were diagnosed at advanced stages of disease. In 80% of the cases, a harmful work 
environment was not identified. Given the low prevalence and the frequent use 
of off-label medicines, it can be considered an orphan disease. Limitations: Only 
limited number of centres was included.
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objeCtives: Motivated by the discussion whether the german AMNOG is applied 
to currently marketed drugs we compared first-line therapies for patients with 
multiple myeloma (MM). Methods: A systematic literature search for randomized 
controlled trials (RCTs) was conducted and VMP (bortezomib (Velcade), melphalan 
and prednisone), MPT (melphalan, prednisone and thalidomide) and MP (melpha-
lan and prednisone) were identified as therapies of interest. We extracted infor-
mation on overall survival (OS), progression-free survival (PFS), response criteria 
(CR, VGPR, PR), and grade 3-4 AEs (any, hematological, non-hematological, DVT, 
PNP). Random-effects meta-analysis was used for direct and the Bucher method 
for adjusted indirect treatment comparison. Results: Seven RCTs with a total of 
2,367 patients were included in our analyses, one RCT (n= 682) comparing VMP vs. 
MP and six RCTs (n= 1,685) comparing MPT vs. MP. Direct head-to-head comparison 
of  VMP vs. MPT was lacking. For MPT vs. MP, data were extracted from a recently 
published meta-analysis of individual patient data if available. VMP was superior to 
MP regarding OS. Both VMP and MPT were superior to MP regarding PFS and response 
criteria, but had a higher risk of developing AEs. The indirect comparison of VMP 
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of these patients receiving 3-line therapy differed significantly in Moscow and St. 
Petersburg, as compared with other regions. ConClusions: Obtained clinical and 
epidemiological data made it possible to fill in the model of management of patients 
with breast cancer in particular regions of Russia.
PCN27
ProjeCtiNg health gaiNs: the PoPulatioN imPaCt of NeW treatmeNts 
to metastatiC Breast CaNCer
Lucas R.1, Andrade S.2, Barros H.1
1Medical School, University of Porto, Porto, Portugal, 2Roche Farmaceutica Quimica, Amadora, 
Portugal
objeCtives: Breast cancer is a leading cause of oncological death among Portuguese 
women but a decline in age-standardized mortality rates is well documented and 
due to an increasing frequency of early diagnosis (more than 85% of the women 
aged 45-69 years, underwent a screening mammography according to the most 
recent national health survey) and access to more efficient treatments, including 
adjuvant and neoadjuvant chemotherapy. However, certain tumor characteristics, 
such as Human epidermal growth factor receptor 2 (HER2) -positive breast cancer, 
are associated with poor prognosis for patients with both early and metastatic 
breast cancer. Methods: Previous studies showed that trastuzumab was expected 
to prevent metastases in about 700 women during 10 years if used in early breast 
cancer, in Portugal. T-DM1 significantly prolonged progression-free (3 m) and over-
all survival (6 m) compared to lapatinib plus capecitabine in patients with HER2-
positive advanced breast cancer previously treated with trastuzumab and a taxane. 
Also, the combination of pertuzumab, trastuzumab, docetaxel, as compared with 
placebo, trastuzumab, docetaxel, when used as first-line treatment for HER2-positive 
metastatic breast cancer, significantly prolonged progression-free survival. These 
trials data and population epidemiological information is used to fit predictive 
models adjusting for available confounders. Results: Although high quality data 
on patients with HER2-positive metastatic disease regarding age and other potential 
health differences is lacking, particularly in Portugal, we modeled population meas-
ures of frequency and applied data describing the clinical epidemiology of meta-
static breast cancer to anticipate the potential impact of these treatment options on 
the quality and the quantity of life of affected individuals, taking into consideration 
the period 2014-24. Additionally, by contrasting the available alternatives, we will 
present an estimation of the averted expenses regarding treatment options for the 
same period. ConClusions: The study provides information on health gains and 
evidence for decision making.
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objeCtives: The latest available published oncology national data from the Slovak 
Republic (SR) are for year 2008. The objective of this analysis was to evaluate long-
term national trends of breast cancer (BC) incidence, mortality, clinical stages and 
prevalence to obtain more actual data for the purpose of cost-of-illness studies 
and budget impact analysis in the SR. Methods: Time-trends of national data 
on incidence, mortality, clinical stages and prevalence of BC in 1978-2008 were 
analyzed by using joint-point regression (Version 4.0.4. - May 2013). The data were 
predicted to the current year 2014. The trends are presented with a correspond-
ing 95% Confidence Intervals (CI) and p-value with null hypothesis being constant 
with time. Results: In 2008, BC age-standardized incidence in the SR represented 
59.8/100,000 females (n= 2.639 cases, mean age of women= 61.9 y.), in 1978-2008 the 
incidence was increasing continuously with annual percentage change (APC) of 2.2% 
(95% CI= 2.1-2.3, p< 0.0001), estimation for 2014 is 63.8/100,000 (n= 3.081). Mortality 
in 2008 represented 15.2/100,000 (n= 751) with four join-points and decreasing trend 
from 2001 by APC -3.6% (95% CI= -7.2-0.1, p< 0.04), estimation for 2014 is 14.0/100,000 
(n= 820). National prevalence in 1978-2008 represents 22.118 cases, for 2014 estimate 
is 29.012. According to the national data, in 2014 we estimate 32.6% of patients 
diagnosed in the 1st clinical stage, 36.2% in the 2nd, 16.4% in the 3rd, 7.0% in the 
4th and 7.8% in the undefined clinical stage. The number of cases diagnosed in the 
1st clinical stage is increasing during the time. Despite the observed increase in the 
values of BC incidence, the decrease in mortality has manifested itself in recent 
years. ConClusions: Actual data on incidence, mortality, prevalence and clinical 
stages of BC in the SR can be used as the source for setting the size of population 
in cost-of-illness studies and budget impact analysis.
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objeCtives: Stage IB cutaneous melanomas are characterized by a low risk for 
recurrence and a high survival. However, empirical evidence on recurrence patterns 
and survival subsequent to recurrence is limited. We investigated overall survival 
(OS) and recurrence patterns, and assessed whether the time-to-recurrence was 
associated with prognostic factors. Methods: The Dutch Comprehensive Cancer 
Centers registry was used to identify patients diagnosed with stage IB melanoma 
between January 2003 and December 2011 in six Dutch hospitals including two 
academic and four general hospitals (n= 971). Data were retrospectively collected 
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objeCtives: Treatment of multiple myeloma (MM) consists of a consecutive appli-
cation of various treatment modalities. The optimal sequence of different treat-
ment combinations is unclear. There is a need for the establishment of an analytic 
framework comparing overall survival (OS) of different treatment sequences in MM. 
This analysis contains the first attempt to create such a framework. Methods: 
We performed a systematic literature review (SLR) on treatments compared in 
randomized controlled trials in newly diagnosed and relapsed MM patients. The 
following treatment/combinations were considered; melphalan/prednisone (MP), 
dexamethasone (D), thalidomide (T), bortezomib (V) and lenalidomide (R). Response, 
time to next treatment (TTNT) and OS data were extracted. Response rates were 
derived and pooled for each treatment and treatment line using ordered logistic 
network meta-analysis. The pooled estimates were combined in a Markov model 
framework with treatment switch and mortality transition probabilities to predict 
OS. Seventeen sequences were tested, one starting with MPR and four for each 
starting with MP, MPT, MPV and MPVT. Results: Estimations on the basis of the 
Markov model showed that median OS varied between 40-43,42-45,43,44-47 and 
46-49 months for sequences starting with MP, MPT, MPR, MPV and MPVT, respec-
tively. ConClusions: This study shows a first attempt to build an analytic frame-
work comparing OS of treatment sequences in MM. The absolute results should be 
interpreted with caution, as MM is a heterogeneous disease and the model does 
not yet capture all subtleties related to sequential treatment in clinical practice. 
However, face validity of these first results seem promising and warrant further 
development of this analytic framework.
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objeCtives: The effect of having a positive anaplastic lymphoma receptor tyrosine 
kinase (ALK) mutation on the burden of disease in Stage IV non-small cell lung 
cancer (NSCLC) is unknown. This study compared the burden of disease in ALK 
positive Stage IV NSCLC with ALK negative Stage IV NSCLC. Methods: Burden 
of disease by ALK mutation status was evaluated in Egypt, Russia, and the United 
Arab Emirates (UAE) using disability adjusted life years (DALYs). A burden of disease 
model was developed in line with World Health Organisation (WHO) guidelines. 
Epidemiological data were collected by a survey disseminated during interviews in 
at least three centres per country. Disability weights were obtained from a Dutch 
study. Discounting, age-weighting and life expectancies were based on the WHO 
reference case. Sensitivity analyses were conducted to test the level of uncertainty 
in the model results. Results: Total DALYs across the countries were lower in ALK 
positive disease compared to ALK negative disease (833 vs. 2611). On a per country 
basis, total DALYs were higher in ALK positive disease compared to ALK negative 
disease for Egypt (22 vs. 11) and UAE (229 vs. 219) but lower for Russia (582 vs. 
2381). DALYs per incident case of the disease were consistently higher across the 
countries in ALK positive disease compared to ALK negative disease (Egypt: 11.24 
vs. 10.85; Russia: 9.38 vs. 4.97; UAE: 15.29 vs. 7.82). Results were sensitive to changes 
in discounting, age-weighting, deaths, and incidences. ConClusions: The study 
would suggest that the greatest burden of disease lies in the population with ALK 
negative Stage IV NSCLC compared to ALK positive Stage IV NSCLC, although this 
finding varied between countries. However, it was consistently found that a single 
patient with Stage IV NSCLC will have a greater burden of disease if their ALK 
mutation test is positive.
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objeCtives: In Russia, breast cancer (BC) took first place in the structure of cancer 
incidence and mortality in the female population. Modern therapeutic approaches 
advanced breast cancer (ABC) can achieve clinically significant regression of symp-
toms, prolong life and improve its quality. Aim of this study was to conduct clinical 
and epidemiological analysis of reference postmenopausal patients with hormone- 
(HR+), HER2-ABC in Russia. Methods: Survey of experts from different regions 
of Russia. The questionnaire included the following questions: the proportion of 
patients with different types of breast cancer; drugs and modes of their appoint-
ment as the first, second and third-line treatment of patients postmenopausal 
HR+, HER2-ABC; hospitalization rate per year; laboratory and instrumental methods 
of research, consulting, adverse events with the use of drugs in the treatment of 
patients and their drug regimes correction. Results: From 13 regions of Russia 7 
experts refused to provide information on the questionnaire, which may indicate 
a reluctance to disclose information on the epidemiology and the tactics of the 
disease. Data were obtained from the regions - Moscow, Saint Petersburg, Republic 
of Khakassia, Omsk region, Primorsky Krai, Krasnoyarsk Krai. Share of the growth 
of new breast cancer patients is 10,5-29,6% (median 13.4%) per year. Number of 
patients with ABC from patients with breast cancer is 9,2-53% (median-30%). On 
average, 70% of patients with ABC are in menopause. Number of patients with HR+, 
ER2-ABC at the end of 2013 amounted to Moscow-1772, St. Petersburg-492, Republic 
of Khakassia-188, Omsk region-344, Primorsky Krai-358, Krasnoyarsk Krai-3471. The 
average frequency of hospitalizations in these patients is 6 times a year. Proportion 
